Iovance Biotherapeutics Inc
IOVA
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.7B
Close$
$-0.19
102.3% downside
Current Fair Value
102.3% downsideOvervalued by 102.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.70 Billion |
|---|---|
| Enterprise Value | $3.64 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.09 |
| Beta | 0.7 |
| Outstanding Shares | 450,189,000 |
Return
| Return on Equity | -39.33% |
|---|---|
| Return on Assets | -31.62% |
| Return on Invested Capital | -35.73% |
Valuation & Multiples
| P/E Ratio | -11.84 |
|---|---|
| PEG | 20.55 |
| Price to Sales | - |
| Price to Book Ratio | 8.39 |
| Enterprise Value to Revenue | 11.19 |
| Enterprise Value to EBIT | -12.59 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
$87.83 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.10
Average shareholder expectationRevenue Estimate
$109.00 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.0658▲ 49.82% |
|---|---|
| Total Calls | 3,160,411▲ 9.03% |
| Total Puts | 3,368,407▲ 104.72% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 64.27%▼ 0.00% |
|---|---|
| Total Invested | $943.36M▲ 31.88% |
| Investors Holding | 301▲ 26.00% |
ESG Score
No data
About Iovance Biotherapeutics Inc
CEO: Maria Fardis